For example, a phase II trial of 22 patients investigated the benefit of IFN-γ-matured dendritic cell exosomes, also called “dexosomes” (IFN-γ-Dex), loaded with MHC class I- and class II- restricted cancer antigens as a maintenance immunotherapy after chemotherapy induction in patients with stage IIIB and IV unresectable NSCLC without tumor progression [133,134] (Figure 3). This evidence concerns the gene IFNG and neoplasm.